Psychedelic Spotlight News

  • A Deep Dive Into MindMed’s Microdosing Program: Project Flow | Plus a NEW LSD Microdosing Study

    Learn, Videos

    In today’s episode, we look at MindMed’s (Nasdaq: MNMD, NEO: MMED) Project Flow, which is their LSD microdosing division. At present, MindMed’s microdosing program is split into 2 projects: base testing of LSD microdoses in healthy individuals, and using LSD microdoses to treat adult ADHD.

    We will explore the progress made on both fronts, and where the program will expand to in the future, such as psilocybin (magic mushrooms) microdosing.
    Ultimately, MindMed wants to answer questions such as:

    Can microdosing psychedelics treat ADHD?
    Can microdosing LSD improve your concentration?
    Can microdosing decrease your anxiety?
    Does microdosing increase creativity?
    Does microdosing improve your mood?

    Recently MindMed announced they are ready to begin recruiting for a study testing the variations in effect when taking LSD microdoses in the morning, compared to at night. The study will also try to answer the last four above questions. We discuss this study extensively.

    Links:
    MindMed Project Flow: https://mindmed.co/psychedelic-inspired/#scroll_section-2
    MindMed New study: https://psilocybinalpha.com/news/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures

    Imperial College of London study: https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds

    Project Albert Quote: https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

    Kim Kuypers Study: https://www.nature.com/articles/s41598-021-01811-4

    MindMed Investor’s Deck: https://mindmed.co/wp-content/uploads/2021/11/MindMed-Presentation-11.17-compressed.pdf

    LSD for ADHD: https://mindmed.co/news/press-release/mindmed-advances-phase-2-lsd-microdosing-trial-for-adult-adhd-appoints-principal-investigator/
    https://mindmed.co/news/press-release/mindmeds-microdosing-division-further-expands-phase-2-clinical-trial-of-microdosing-lsdfor-adult-adhd/

    Previous MindMed LSD study: https://mindmed.co/news/press-release/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd/

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy
    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Mindmed #MNMDstock #Microdosing

  • We NEED to Talk about the Compass Pathways Psilocybin-for-Depression Trial Results: A WIN for CMPS??

    Listen, Videos

    In today’s episode, we discuss the results of the much awaited phase 2b clinical trial using psilocybin (comp360) to treat treatment-resistant-depression. This Compass Pathways (Nasdaq: CMPS) trial is so important for a couple of reasons: first, it is the largest ever psychedelics clinical trial, with 219 people completing the trial; and second because it is the furthest progressed psilocybin trial ever, being in phase 2b.

    So what did the results say? Can Magic Mushrooms treat depression? Can Psychedelics help Mental Health?

    Well, the results are mixed. About a quarter of the people who underwent Compass Pathways psychedelic therapy program, who received 25 mg of psilocybin (Comp 360), entered remission after 12 weeks. And almost a third of individuals in this group saw their depression symptoms decrease by 50% or more, as measured by the MADRS scale. This is more than double the success rate for the control group, showing strong significant effects of psilocybin therapy on depression. Therefore, it is clear that psychedelics like psilocybin CAN help mental health… at least somewhat
    However, many, myself included, were hoping for stronger results, such as the MDMA to treat PTSD phase 3 results that MAPS released earlier this year. This led to disappointment at the positive results, as they were not as game changing as we had hoped.
    In this episode, we describe Compass Pathways’ psilocybin for depression clinical trial, explain the results, and then try to put said results into context. We finish by looking towards the future, and discussing where Compass Pathways, and other psychedelic medicines companies like MindMed, Cybin and Small Pharma, should go from here.

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Links:
    Compass Results: https://ir.compasspathways.com/static-files/0f9fbce8-2619-438b-a6ba-5bbe2ba08cf6
    Montgomery-Asberg Depression Rating Scale (MADRS):
    https://en.wikipedia.org/wiki/Montgomerysberg_Depression_Rating_Scale

    MAPS MDMA-PTSD Study:
    https://www.nytimes.com/2021/05/03/health/mdma-approval.html

    Comp 360 Open Label Study:
    https://www.globenewswire.com/en/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html

    MindMed Psilocybin SSRI Study:
    https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #psilocybin #depression